Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?

Publisher： Bentham Science Publishers

E-ISSN： 2212-3970|2|2|135-142

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.2, Iss.2, 2007-06, pp. : 135-142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Matrix metalloproteinase inhibitors in the treatment of cancer

By Brown Peter  

Medical Oncology, Vol. 14, Iss. 1, 1997-03 ,pp. : 1-10

Humana Press, Inc

Access to resources Recommend Favorite

Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway

By              

Oncology Reports, Vol. 30, Iss. 2, 2013-01 ,pp. : 933-938

Spandidos Publications

Access to resources Recommend Favorite

Stereotactic Body Radiotherapy (SBRT) in the Management of Clinically Localized Prostate Cancer: Where are We Now?

By  

Current Cancer Therapy Reviews, Vol. 14, Iss. 1, 2018-02 ,pp. : 31-45

Bentham Science Publishers

Access to resources Recommend Favorite

Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer*

By Tunuguntla R.   Ripley D.   Sang Q.-X.A.   Chegini N.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 453-459

Elsevier

Access to resources Recommend Favorite

Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity

By Takano Shingo  

Brain Tumor Pathology, Vol. 27, Iss. 2, 2010-10 ,pp. : 89-94

Springer Publishing Company

Access to resources Recommend Favorite